Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Cash from Financing Activities for 3 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 60.88% to $28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.9 million through Dec 2025, up 5.9% year-over-year, with the annual reading at $75.9 million for FY2025, 5.9% up from the prior year.
  • Cash from Financing Activities hit $28.6 million in Q4 2025 for Camp4 Therapeutics, down from $47.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $73.1 million in Q4 2024 to a low of -$812000.0 in Q2 2024.
  • Historically, Cash from Financing Activities has averaged $16.4 million across 3 years, with a median of -$63000.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 116071.43% in 2024 and later tumbled 60.88% in 2025.
  • Year by year, Cash from Financing Activities stood at -$63000.0 in 2023, then surged by 116071.43% to $73.1 million in 2024, then crashed by 60.88% to $28.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CAMP at $28.6 million in Q4 2025, $47.4 million in Q3 2025, and $72000.0 in Q2 2025.